L. Petri, A. Egyed, D. Bajusz et al.
European Journal of Medicinal Chemistry 207 (2020) 112836
[26] E. Awoonor-Williams, C.N. Rowley, How reactive are druggable cysteines in
protein kinases? J. Chem. Inf. Model. 58 (9) (2018) 1935e1946, https://
[50] J. Kempson, D. Ovalle, J. Guo, S.T. Wrobleski, S. Lin, S.H. Spergel, J.J.-W. Duan,
B. Jiang, Z. Lu, J. Das, et al., Discovery of highly potent, selective, covalent
inhibitors of JAK3, Bioorg. Med. Chem. Lett 27 (20) (2017) 4622e4625, https://
[27] Z. Zhao, Q. Liu, S. Bliven, L. Xie, P.E. Bourne, Determining cysteines available
for covalent inhibition across the human kinome, J. Med. Chem. 60 (7) (2017)
[28] R. Liu, Z. Yue, C.-C. Tsai, J. Shen, Assessing lysine and cysteine reactivities for
designing targeted covalent kinase inhibitors, J. Am. Chem. Soc. 141 (16)
[29] W. Zhang, J. Pei, L. Lai, Statistical analysis and prediction of covalent ligand
targeted cysteine residues, J. Chem. Inf. Model. 57 (6) (2017) 1453e1460,
[30] J.S. Murray, P. Politzer, The electrostatic potential: an overview, Wiley Inter-
[31] G. Naray-Szabo, G.G. Ferenczy, Molecular electrostatics, Chem. Rev. 95 (4)
[32] M.S. Cohen, Structural bioinformatics-based design of selective, irreversible
[33] E. Leproult, S. Barluenga, D. Moras, J.-M. Wurtz, N. Winssinger, Cysteine
mapping in conformationally distinct kinase nucleotide binding sites: appli-
cation to the design of selective covalent inhibitors, J. Med. Chem. 54 (5)
[51] J.-B. Telliez, M.E. Dowty, L. Wang, J. Jussif, T. Lin, L. Li, E. Moy, P. Balbo, W. Li,
Y. Zhao, et al., Discovery of a JAK3-selective inhibitor: functional differentia-
tion of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition,
[52] A. Thorarensen, M.E. Dowty, M.E. Banker, B. Juba, J. Jussif, T. Lin, F. Vincent,
R.M. Czerwinski, A. Casimiro-Garcia, R. Unwalla, et al., Design of a Janus kinase
3 (JAK3) specific inhibitor 1-((2 S ,5 R )-5-((7 H -Pyrrolo[2,3- d ]Pyrimidin-4-
Yl)Amino)-2-Methylpiperidin-1-Yl)Prop-2-En-1-One (PF-06651600) allowing
for the interrogation of JAK3 signaling in humans, J. Med. Chem. 60 (5) (2017)
[53] M. Forster, M. Gehringer, S.A. Laufer, Recent advances in JAK3 inhibition:
isoform selectivity by covalent cysteine targeting, Bioorg. Med. Chem. Lett 27
[54] L. He, M. Shao, T. Wang, T. Lan, C. Zhang, L. Chen, Design, synthesis, and SAR
study of highly potent, selective, irreversible covalent JAK3 inhibitors, Mol.
[55] R. Gunasekar, P. Thamaraiselvi, R.S. Rathore, K.I. Sathiyanarayanan,
S. Easwaramoorthi, Tuning the electronic properties of 2-cyano-3-
phenylacrylamide derivatives, J. Org. Chem. 80 (24) (2015) 12351e12358,
[34] Q. Liu, Y. Sabnis, Z. Zhao, T. Zhang, S.J. Buhrlage, L.H. Jones, N.S. Gray, Devel-
oping irreversible inhibitors of the protein kinase cysteinome, Chem. Biol. 20
[35] E. Awoonor-Williams, A.G. Walsh, C.N. Rowley, Modeling covalent-modifier
drugs, Biochim. Biophys. Acta Protein Proteonomics 1865 (11) (2017)
[56] N. London, R.M. Miller, S. Krishnan, K. Uchida, J.J. Irwin, O. Eidam, L. Gibold,
ꢁ ꢁ
P. Cimermancic, R. Bonnet, B.K. Shoichet, et al., Covalent docking of large li-
braries for the discovery of chemical probes, Nat. Chem. Biol. 10 (12) (2014)
[57] L. Ren, B. Deng, V. Saloura, J. Park, Y. Nakamura, MELK inhibition targets
cancer stem cells through downregulation of SOX2 expression in head and
[58] A. Chlenski, C. Park, M. Dobratic, H.R. Salwen, B. Budke, J.-H. Park, R. Miller,
M.A. Applebaum, E. Wilkinson, Y. Nakamura, et al., Maternal embryonic
leucine zipper kinase (MELK), a potential therapeutic target for neuroblas-
[36] D.A. Erlanson, S.W. Fesik, R.E. Hubbard, W. Jahnke, H. Jhoti, Twenty years on:
the impact of fragments on drug discovery, Nat. Rev. Drug Discov. 15 (9)
ꢀ
ꢀ
}
[37] A. Keeley, L. Petri, P. Abranyi-Balogh, G.M. Keseru, Covalent fragment libraries
[38] E.H. Krenske, R.C. Petter, K.N. Houk, Kinetics and thermodynamics of revers-
ible thiol additions to mono- and diactivated michael acceptors: implications
for the design of drugs that bind covalently to cysteines, J. Org. Chem. 81 (23)
[39] M.E. Flanagan, J.A. Abramite, D.P. Anderson, A. Aulabaugh, U.P. Dahal,
A.M. Gilbert, C. Li, J. Montgomery, S.R. Oppenheimer, T. Ryder, et al., Chemical
and computational methods for the characterization of covalent reactive
groups for the prospective design of irreversible inhibitors, J. Med. Chem. 57
[59] A. Cigliano, M.G. Pilo, M. Mela, S. Ribback, F. Dombrowski, G.M. Pes, A. Cossu,
M. Evert, D.F. Calvisi, K. Utpatel, Inhibition of MELK protooncogene as an
innovative treatment for intrahepatic cholangiocarcinoma, Medicina (B Aires)
ꢀ
[60] M.H. Meel, M. Guillen Navarro, M.C. de Gooijer, D.S. Metselaar, P. Waranecki,
M. Breur, T. Lagerweij, L.E. Wedekind, J. Koster, M.D. van de Wetering, et al.,
MEK/MELK inhibition and bloodebrain barrier deficiencies in atypical ter-
[40] V.J. Cee, L.P. Volak, Y. Chen, M.D. Bartberger, C. Tegley, T. Arvedson,
J. McCarter, A.S. Tasker, C. Fotsch, Systematic study of the glutathione (GSH)
reactivity of N -arylacrylamides: 1. Effects of aryl substitution, J. Med. Chem.
[61] I.M. McDonald, G.D. Grant, M.P. East, T.S.K. Gilbert, E.M. Wilkerson,
D. Goldfarb, J. Beri, L.E. Herring, C. Vaziri, J.G. Cook, et al., Mass
spectrometryebased selectivity profiling identifies a highly selective inhibitor
of the kinase MELK that delays mitotic entry in cancer cells, J. Biol. Chem. 295
ꢀ
ꢀ
}
[41] L. Petri, P. Abranyi-Balogh, P.R. Varga, T. Imre, G.M. Keseru, Comparative
reactivity analysis of small-molecule thiol surrogates, Bioorg. Med. Chem. 28
}
€
[42] G.G. Ferenczy, G.M. Keseru, Thermodynamics of fragment binding, J. Chem.
[63] D. Wondrousch, A. Bohme, D. Thaens, N. Ost, G. Schüürmann, Local electro-
[43] P.K. Chattaraj, U. Sarkar, D.R. Roy, Electrophilicity index, Chem. Rev. 106 (6)
philicity predicts the toxicity-relevant reactivity of michael acceptors, J. Phys.
ꢀ
ꢀ
ꢀ
[44] P. Abranyi-Balogh, L. Petri, T. Imre, P. Szijj, A. Scarpino, M. Hrast, A. Mitrovic,
ꢁ
ꢀ
U.P. Fonovic, K. Nemeth, H. Barreteau, et al., A road map for prioritizing
warheads for cysteine targeting covalent inhibitors, Eur. J. Med. Chem. 160
ꢀ
[65] B.B. Toure, J. Giraldes, T. Smith, E.R. Sprague, Y. Wang, S. Mathieu, Z. Chen,
[45] G. Manning, The protein kinase complement of the human genome, Science
[46] M. Chartier, T. Chenard, J. Barker, R. Najmanovich, Kinome Render, A stand-
alone and web-accessible tool to annotate the human protein kinome tree,
[47] A. Vasudevan, M.A. Argiriadi, A. Baranczak, M.M. Friedman, J. Gavrilyuk,
A.D. Hobson, J.J. Hulce, S. Osman, N.S. Wilson, Covalent binders in drug dis-
[48] E.R. Goedken, M.A. Argiriadi, D.L. Banach, B.A. Fiamengo, S.E. Foley, K.E. Frank,
J.S. George, C.M. Harris, A.D. Hobson, D.C. Ihle, et al., Tricyclic covalent in-
hibitors selectively target Jak3 through an active site thiol, J. Biol. Chem. 290
[49] L. Tan, K. Akahane, R. McNally, K.M.S.E. Reyskens, S.B. Ficarro, S. Liu,
G.S. Herter-Sprie, S. Koyama, M.J. Pattison, K. Labella, et al., Development of
selective covalent Janus kinase 3 inhibitors, J. Med. Chem. 58 (16) (2015)
Y. Mishina, Y. Feng, Y. Yan-Neale, et al., Toward the validation of maternal
embryonic leucine zipper kinase: discovery, optimization of highly potent and
selective inhibitors, and preliminary biology insight, J. Med. Chem. 59 (10)
[66] K. Zhu, K.W. Borrelli, J.R. Greenwood, T. Day, R. Abel, R.S. Farid, E. Harder,
Docking covalent inhibitors: a parameter free approach to pose prediction
[67] R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz,
M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, et al., Glide: a new approach for
rapid, accurate docking and scoring. 1. Method and assessment of docking
ꢀ
[68] M.P. Jacobson, D.L. Pincus, C.S. Rapp, T.J.F. Day, B. Honig, D.E. Shaw,
R.A. Friesner, A hierarchical approach to all-atom protein loop prediction,
9